NeuBase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Other Prepaid Expenses and Other Current Assets

6 Months Ended

Mar. 31, 2022

3. Other Prepaid Expenses and Other Current Assets

The Company’s prepaid expenses and other current assets consisted of the following:


	As of March 31,		As of September 30,
	2022		2021
Prepaid research and development expense	$	622,237	$	583,267
Prepaid rent		—		172,518
Other prepaid expenses and other current assets		529,742		780,401
Total	$	1,151,979	$	1,536,186